Tom Isett, iBio CEO
CDMO makes an AI and drug discovery play in latest, small-time acquisition
The CDMO outfit iBio has netted a deal that sees it gain access to an AI-based platform as well as new therapeutic candidates as it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
